Bio Details

Dr. Anne Prener has been a member of our Board of Directors since 2021. Dr. Prener has more than 25 years of leadership experience within life sciences companies and has led companies and teams across several therapeutic areas, including most recently cardiovascular diseases as CEO and President of Imbria Pharmaceuticals, Inc., where she led the company through three phase 2 clinical trials. As CEO of Freeline, ltd, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline., two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform. Prior to joining Freeline, she served as Chief Executive Officer of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. During her time at Baxalta, three new major product approvals in the U.S. and EU were secured along with a significant advancement in Baxalta’s hematology portfolio. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio, where she was instrumental in building a portfolio of late stage and commercial hemophilia products. She previously served on the board of several life science companies, including Rubius Therapeutics, Kaleido Bioscience and Renovacor. Dr. Prener holds a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.